<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669393</url>
  </required_header>
  <id_info>
    <org_study_id>THR-317-003</org_study_id>
    <secondary_id>2017-004010-26</secondary_id>
    <nct_id>NCT03669393</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)</brief_title>
  <official_title>A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxurion</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the safety of THR-317 when administered intravitreally
      and to assess the compound's efficacy in reducing central subfield thickness (CST) and
      improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1
      (MacTel 1).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in central subfield thickness (CST), based on spectral domain optical coherence tomography (SD-OCT)</measure>
    <time_frame>At Day 84 (Month 3)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CST, based on SD-OCT, by study visit</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in area of cystoid spaces, based on SD-OCT, by study visit</measure>
    <time_frame>From baseline to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in best-corrected visual acuity (BCVA), by study visit</measure>
    <time_frame>From Day 0 to Day 140</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic and ocular adverse events including serious adverse events</measure>
    <time_frame>From Day 0 to Day 140</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Retinal Telangiectasis</condition>
  <condition>Idiopathic Juxtafoveal Retinal Telangiectasia</condition>
  <arm_group>
    <arm_group_label>THR-317</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-317 8mg</intervention_name>
    <description>3 intravitreal injections of THR-317 8mg, approximately 1 month apart</description>
    <arm_group_label>THR-317</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Macular oedema caused by MacTel 1, with CST &gt;300µm on SD-OCT

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  Type 1 or type 2 Diabetes Mellitus

          -  Concurrent disease in the study eye that could require medical or surgical
             intervention during the study period for up to 30 days after the last study treatment,
             or could confound interpretation of the results

          -  Previous confounding treatments / procedures, or their planned / expected use during
             the study period for up to 30 days after the last administration of study treatment

          -  Any active ocular / intraocular infection or inflammation in either eye

          -  Pregnant or lactating female, or female of child-bearing potential not utilising an
             adequate form of contraception, or male of reproductive potential not utilising
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>Oxurion NV.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Global Clinical Development</last_name>
    <phone>+32 (0)16 751 310</phone>
    <email>info@thrombogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ophtalmique Jules-Gonin</name>
      <address>
        <city>Lausanne</city>
        <zip>1000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>July 1, 2019</last_update_submitted>
  <last_update_submitted_qc>July 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Telangiectasis</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

